The pair will anchor Bright Angel Therapeutics as founding shareholders, providing resources to drive an antifungal enhancement program advancing discoveries made at MIT and University of Toronto.
Bright Angel Therapeutics, a Canada-based fungal inhibitor developer based on Massachusetts Institute of Technology (MIT) and University of Toronto research, was publicly unveiled today to develop drugs that help overcome resistance to existing antifungal medicines.
Multi-university commercialisation firm Mars Innovation and drug discovery company Schrödinger are the company’s founding shareholders, however further details of their agreement were not disclosed.
Founded in 2016, Bright Angel hopes to develop a drug that inhibits the chaperone protein Hsp90, which is thought to be crucial in stimulating biological resistance to antifungal medications.
The drug would complement existing antifungal treatments to overcome rising resistance observed to cause severe morbidity and mortality in patients with diversified fungal infections.
Under the founding agreement, Bright Angel will have to access Schrödinger’s computational drug discovery platforms to design up to three drug leads, while Mars Innovation will provide the company with startup services in addition…
